{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-008072","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.193566+00:00","generated_at":"2026-06-27T03:00:35.330533+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenon Pharmaceuticals enters amended ATM equity offering agreement for up to $250M","bullets":["Amendment to August 2020 ATM sales agreement with Jefferies and Stifel, filed March 1, 2022.","Company may offer and sell up to $250 million of common shares at-the-market on Nasdaq.","Sales agents Jefferies and Stifel will receive up to 3.0% commission on gross proceeds.","No minimum obligation to sell; program may be terminated by either party upon written notice.","Shares sold under existing shelf registration statement (File No. 333-260010) and prospectus supplement."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-008072","json":"https://secwatch.observer/filing/0001564590-22-008072.json","markdown":"https://secwatch.observer/filing/0001564590-22-008072.md","text":"https://secwatch.observer/filing/0001564590-22-008072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000156459022008072/0001564590-22-008072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000156459022008072/xene-8k_20220301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:00:35.330533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}